Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Transferable Trustworthy Radiotherapy with Artificial Intelligence

Objetivo

Cancer is the leading cause of death in Europe and the second worldwide. Over 50% of patients are treated with Radiotherapy (RT) and it accounts for 40% of cures, yet recurrence and toxicities remain significant challenges. Despite major advances in imaging, planning and delivery, RT still largely follows a “one-dose-fits-all” approach, leading to variable outcomes, toxicities and limited adaptability to patient-specific biology. Europe is currently undergoing a digital transformation driven by AI, advanced imaging and the European Health Data Space, but current AI solutions in RT remain fragmented, poorly generalizable and insufficiently explainable, preventing their safe deployment in clinical practice.
TTRAIL aims at improving the safety, precision and personalization of radiotherapy (RT) by training 15 Doctoral Candidates as the first generation of Translational AI Radiotherapy Scientists, capable of uniting AI innovation with clinical radiotherapy, medical physics, regulatory science and digital-health translation. Their training will span multiscale data integration, uncertainty quantification, explainable and causal outcome modelling, digital twins and real-time adaptive dose delivery, aligned with the EU AI Act.
The consortium unites top European universities, engineering schools, cancer centers and major industrial partners, providing access to cutting-edge RT platforms, large multicentre datasets and expertise across AI, imaging, oncology, physics and regulatory compliance. This intersectoral ecosystem ensures robust scientific training, clinical immersion, industrial exposure and strong open-science practices.
By delivering a fully integrated, trust-by-design framework for AI-enabled Adaptive Radiotherapy, TTRAIL will produce highly skilled researchers able to lead the future of personalised, safe and explainable cancer treatment in Europe.

Ámbito científico (EuroSciVoc)

Este proyecto aún no se ha clasificado con EuroSciVoc.
Sugiera los ámbitos científicos que considere más relevantes y ayúdenos a mejorar nuestro servicio de clasificación.

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-MSCA-2025-DN-01

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

UNIVERSITE DE RENNES
Aportación neta de la UEn
€ 629 338,32
Dirección
263 AVENUE DU GENERAL LECLERC
35042 Rennes
Francia
Región
Bretagne Bretagne Ille-et-Vilaine
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
Sin datos

Participantes (10)

Socios (13)